Vancouver, BC – March 20, 2015 – InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF),a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, today announced that it has received notice that InMed will be added to the CSE Composite Index effective after the close on Friday, March 20, 2015